Antengene公司在B轮融资中筹集了1.2亿美元

StephenW

Antengene Corporation Raises $120 Million in Series B Financing

News provided by
Antengene Corporation

Jan 01, 2019, 19:15 ET

Share this article

SHANGHAI and SHAOXING, China, Jan. 1, 2019 /PRNewswire/ -- Antengene Corporation (Antengene), a clinical stage therapeutics company focused on oncology, announced today that it has completed a $120 million Series B financing. The Series B financing was jointly led by Boyu Capital and FountainVest, with participation from Celgene Corporation, WuXi Corporate Venture Fund, and Taikang. Previous investors, Qiming Venture Partners and TF Capital, also participated in this round. This new round follows a $21 million Series A financing in 2017, led by Qiming Venture Partners.

Founded in 2017, Antengene is a biopharmaceutical company that focuses on the development and commercialization of novel therapeutics. Headquartered in China, Antengene is committed to delivering innovative drugs and combination therapies to diseases with high unmet medical needs in China and the Asia-Pacific region.

Proceeds from the financing will be primarily used to fund the continuing development of the company's lead programs ATG-008 and ATG-010 (selinexor) and other clinical-stage assets, to expand the company's pipeline through internal R&D and external partnerships, and to prepare the commercial launch of late-stage drug candidates. A 169,984 square feet manufacturing and research facility in Shaoxing, China, currently undergoing construction for GMP manufacturing, will provide both the clinical and commercial drug supply for the company's pipeline products.

ATG-010 (selinexor) is a first-in-class Selective Inhibitor of Nuclear Export (SINE) compound in late clinical development for the treatment of multiple hematological malignancies and solid tumors, including multiple myeloma, diffuse large B-cell lymphoma, liposarcoma, etc. ATG-008 is a second generation TORC1/2 inhibitor currently in late stage development for the treatment of hepatitis B virus positive (HBV+) hepatocellular carcinoma. This program has also been selected as a "Key Project for Novel Drug Development in China".

"We are grateful for the support and recognition from these prestigious and well-established investors, and that we share a common vision of delivering cutting-edge therapies to help patients with life-threatening diseases. We look forward to creating value for patients, investors and our partners," said Dr. Jay Mei, founder, chairman, and CEO of Antengene. "This round of financing is critical for Antengene's growth. We will continue to maintain and advance rigorous, science-driven, and patient-centered R&D, while actively preparing for the commercialization of our lead products in China and the Asia-Pacific Region."

Commented Yanling Cao, Managing Director of Boyu Capital, "As a long-term investor in China's biopharmaceutical industry, Boyu Capital is much honored to be the lead investor in the Series B financing of Antengene. We view in-licensing of first-in-class/best-in-class drug candidates as an effective solution to the unmet clinical needs in China. In addition, we are very impressed with the progress that Antengene is making and the pipeline they are building. Therefore, we are excited about the opportunity to work with the exceptional team at Antengene and bring novel therapeutics to Chinese and Asian patients."

"In the coming decade, China will rapidly fill the gap in healthcare compared to western countries. This trend will continuously bring opportunities to innovative biopharmaceutical companies such as Antengene. But it also requires patient capital and financial investor with strategic angle. That's how FountainVest position ourselves," said Zhen Li, Managing Director of FountainVest. "We are delighted and fortunate to lead this round of investment in Antengene, and look forward to best deploying FountainVest's resources and expertise in the field to contribute to the healthcare industry in China and the rest of Asia together with Antengene."

About Antengene

Antengene Corporation is a clinical-stage biopharmaceutical company focused on drug discovery, clinical development and the commercialization of innovative therapeutics to meet unmet medical needs in Asia. Antengene aims to provide the most advanced and first-in-class anti-cancer drug treatments for patients in China and rest of Asia. On April 13, 2017, Celgene Corporation (NASDAQ: CELG), a global leading innovative biopharmaceutical company became a long-term strategic partner and obtained an equity position in Antengene. Antengene's pipeline includes five clinical stage products, ranging from Phase 2/3 to NDA stage, including ATG-010 for relapsed/refractory multiple myeloma, lymphomas and solid tumors, and ATG-008, which is in a multi-regional clinical trial that is currently enrolling late stage HCC patients in Taiwan, South Korea and mainland China. Two other Phase 1 and Phase 2 clinical stage drugs, ATG-016 and ATG-019, are being studied in multiple cancer types, including MDS, colorectal and prostate cancers. ATG-527, studied in a completed Phase 1 trial, is being explored for multiple anti-viral indications, including influenza, respiratory syncytial virus (RSV), and Epstein-Barr virus (EBV) related diseases. For more information, please visit www.antengene.com.

StephenW

Antengene公司在B轮融资中筹集了1.2亿美元

新闻提供者
Antengene公司

2019年1月1日，美国东部时间19:15

分享此文章

中国上海和绍兴，2019年1月1日/美通社-PR Newswire /  -  Antengene Corporation（Antengene）是一家专注于肿瘤学的临床阶段治疗公司，今天宣布已完成1.2亿美元的B轮融资。 B系列融资由博宇资本和FountainVest共同领导，参与Celgene公司，无锡企业创业基金和泰康。之前的投资者，启明创业投资公司和TF Capital也参与了此轮融资。此次新一轮融资是在Qiming Venture Partners领导的2017年A轮融资2100万美元之后进行的。

Antengene成立于2017年，是一家生物制药公司，专注于新疗法的开发和商业化。 Antengene总部位于中国，致力于为中国和亚太地区未满足医疗需求的疾病提供创新药物和联合疗法。

融资收益将主要用于资助公司牵头计划ATG-008和ATG-010（selinexor）及其他临床资产的持续发展，以通过内部研发和外部合作伙伴关系扩展公司的管道，并做好准备晚期候选药物的商业推出。位于中国绍兴的169,984平方英尺的制造和研究设施目前正在进行GMP制造建设，将为该公司的管道产品提供临床和商业药品供应。

ATG-010（selinexor）是一种先进的核输出选择性抑制剂（SINE）化合物，用于治疗多种血液系统恶性肿瘤和实体瘤，包括多发性骨髓瘤，弥漫性大B细胞淋巴瘤，脂肪肉瘤， ATG-008是目前用于治疗乙型肝炎病毒阳性（HBV +）肝细胞癌的晚期发展的第二代TORC1 / 2抑制剂。该计划还被选为“中国新药开发重点项目”。

“我们感谢这些着名和成熟的投资者的支持和认可，并且我们有共同的愿景，即提供尖端疗法来帮助患有危及生命的疾病的患者。我们期待为患者，投资者创造价值和我们的合作伙伴，“Antengene的创始人，董事长兼首席执行官Jay Mei博士说。 “这一轮融资对于Antengene的发展至关重要。我们将继续保持并推进严谨，科学驱动，以患者为中心的研发，同时积极准备我们在中国和亚太地区的主导产品的商业化。”

博宇资本董事总经理曹艳玲评论说：“作为中国生物制药行业的长期投资者，博宇资本很荣幸成为Antengene B系列融资的主要投资者。我们认为首先获得许可证。班级/同类最佳候选药物是解决中国未满足临床需求的有效方法。此外，我们对Antengene正在制定的进展及其建设的管道印象深刻。因此，我们对这个机会感到非常兴奋与Antengene的优秀团队合作，为中国和亚洲患者带来新的治疗方法。“

“在未来十年，与西方国家相比，中国将迅速填补医疗保健方面的空白。这一趋势将不断为Antengene等创新生物制药公司带来机遇。但这也需要患者资金和财务投资者的战略角度。这就是FountainVest的立场我们自己，“FountainVest董事总经理李振说。 “我们很高兴和幸运地领导了对Antengene的这一轮投资，并期待最好地部署FountainVest在该领域的资源和专业知识，与Antengene一起为中国和亚洲其他地区的医疗保健行业做出贡献。”
关于Antengene

Antengene Corporation是一家临床阶段的生物制药公司，专注于药物发现，临床开发和创新疗法的商业化，以满足亚洲未满足的医疗需求。 Antengene旨在为中国和亚洲其他地区的患者提供最先进和一流的抗癌药物治疗。 2017年4月13日，Celgene公司（纳斯达克股票代码：CELG）成为全球领先的创新生物制药公司，成为长期战略合作伙伴，并在Antengene获得股权。 Antengene的管道包括五个临床阶段产品，从第2/3阶段到NDA阶段，包括用于复发/难治性多发性骨髓瘤，淋巴瘤和实体瘤的ATG-010，以及在多区域临床试验中的ATG-008。目前正在台湾，韩国和中国大陆招募晚期HCC患者。另外两种1期和2期临床阶段药物ATG-016和ATG-019正在多种癌症类型中进行研究，包括MDS，结肠直肠癌和前列腺癌。 ATG-527在完成的1期试验中进行了研究，正在探索多种抗病毒适应症，包括流感，呼吸道合胞病毒（RSV）和爱泼斯坦 - 巴尔病毒（EBV）相关疾病。欲了解更多信息，请访问www.antengene.com。